Antibodies to gangliosides in guillain-Barré syndrome: Specificity and relationship to clinical features

N. A. Gregson, S. Koblar, R. A C Hughes

Research output: Contribution to journalArticle

96 Citations (Scopus)


Antibodies to ganglioside GM1 have been associated with Guillain-Barré syndrome. To clarify their role we have studied their frequency, fine specificity and relationship to clinical features in a series of patients with this disease. Antibodies to ganglioside GM1 were identified, by both enzyme-linked immunosorbent assay and binding to thin-layer chromatograms of human brain, in 12 (28.6%) of 42 patients with Guillain-Barré syndrome and in only 1 (2.4%) of 41 normal control subjects (p=0.002). Eight sera contained IgM antibodies and six sera contained IgG antibodies, including 2 sera which contained both. The fine specificity of the sera varied. Only four of the 12 sera also showed reactivity with ganglioside GO1b and gangliotetraosyl-ceramide (asialo-GMD, consistent with reactivity with the terminal Galβ1-3GalNAc disaccharide. Two sera had low titre anti-asialo-GM1 antibodies of a different class to the anti-ganglioside GM1 antibodies. The antibodies in these sera therefore react with a variety of epitopes. There was a strong relationship between the presence of anti-ganglioside GM1 antibodies in the acute stage and prolonged disability, especially if IgG antibodies were present. Seven of 12 patients with anti-ganglioside GM1 antibodies had serologi-cal evidence of recent Campylobacter jejuni Infection, but antigens from a strain of this bacterium not associated with Guillain-Barré syndrome did not absorb the anti-ganglioside GM1 antibodies.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
Issue number2
Publication statusPublished - Feb 1993

ASJC Scopus subject areas

  • Medicine(all)

Cite this